These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38557299)

  • 1. Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant.
    Cao Y; Shang J; Zhai Y; Wang Q; Yan L; Shi X; Wang J; Yao Y; Zhou H; Sun A; Miao M; Fu C; Jin S
    Leuk Lymphoma; 2024 Jul; 65(7):1016-1019. PubMed ID: 38557299
    [No Abstract]   [Full Text] [Related]  

  • 2. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
    Rosiñol L; Oriol A; Teruel AI; Hernández D; López-Jiménez J; de la Rubia J; Granell M; Besalduch J; Palomera L; González Y; Etxebeste MA; Díaz-Mediavilla J; Hernández MT; de Arriba F; Gutiérrez NC; Martín-Ramos ML; Cibeira MT; Mateos MV; Martínez J; Alegre A; Lahuerta JJ; San Miguel J; Bladé J;
    Blood; 2012 Aug; 120(8):1589-96. PubMed ID: 22791289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
    Lok A; Mocquard J; Bourcier J; Redelsperger L; Bonnet A; Chauvin C; Thomaré P; Mahé B; Touzeau C; Moreau P
    Haematologica; 2014 Mar; 99(3):e33-4. PubMed ID: 24532044
    [No Abstract]   [Full Text] [Related]  

  • 4. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Moreau P; Avet-Loiseau H; Facon T; Attal M; Tiab M; Hulin C; Doyen C; Garderet L; Randriamalala E; Araujo C; Lepeu G; Marit G; Caillot D; Escoffre M; Lioure B; Benboubker L; Pégourié B; Kolb B; Stoppa AM; Fuzibet JG; Decaux O; Dib M; Berthou C; Chaleteix C; Sebban C; Traullé C; Fontan J; Wetterwald M; Lenain P; Mathiot C; Harousseau JL
    Blood; 2011 Nov; 118(22):5752-8; quiz 5982. PubMed ID: 21849487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
    Schmielau J; Teschendorf C; König M; Schmiegel W; Graeven U
    Leuk Lymphoma; 2005 Apr; 46(4):567-9. PubMed ID: 16019485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib.
    Fett NM; Toporcer MB; Dalmau J; Shinohara MM; Vogl DT
    Am J Hematol; 2011 Oct; 86(10):893-6. PubMed ID: 22026006
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
    Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "IM iD"eally treating multiple myeloma.
    Lacy MQ
    Blood; 2013 Mar; 121(11):1926-8. PubMed ID: 23493767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
    Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
    Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
    [No Abstract]   [Full Text] [Related]  

  • 11. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
    Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
    Mele G; Spina A; Guaragna G; Giannotta A; Melpignano A; Quarta G
    Leuk Lymphoma; 2014 May; 55(5):1191-3. PubMed ID: 23829305
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic news in multiple myeloma. Congress of the French National Society of Internal Medicine, December 2008, Bordeaux].
    Geffray L
    Rev Med Interne; 2009 May; 30(5):465-8. PubMed ID: 19349101
    [No Abstract]   [Full Text] [Related]  

  • 15. Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.
    Kuroda J; Kobayashi T; Tsutsumi Y; Yamamoto M; Ohshiro M; Sasaki N; Shimura Y; Mizutani S; Nagoshi H; Kiyota M; Nakayama R; Uchiyama H; Matsumoto Y; Horiike S; Shimazaki C; Taniwaki M
    Int J Hematol; 2010 Nov; 92(4):669-72. PubMed ID: 20978877
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.
    Chim CS; Lie AK; Chan EY; Leung YY; Cheung SC; Chan SY; Liang R; Kwong YL
    Ann Hematol; 2010 Oct; 89(10):1019-27. PubMed ID: 20428873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients.
    Ciolli S; Leoni F; Gigli F; Rigacci L; Bosi A
    Leuk Lymphoma; 2006 Jan; 47(1):171-3. PubMed ID: 16321846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
    Usmani SZ; Sexton R; Hoering A; Heuck CJ; Nair B; Waheed S; Al Sayed Y; Chauhan N; Ahmad N; Atrash S; Petty N; van Rhee F; Crowley J; Barlogie B
    Blood; 2012 Aug; 120(8):1597-600. PubMed ID: 22674807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of relapsed and refractory myeloma.
    Kaufman J; Gleason C; Lonial S
    Curr Hematol Malig Rep; 2009 Apr; 4(2):99-107. PubMed ID: 20425421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.